• Change in A1C
  (primary endpoint)
• Change in weight
  (2° endpoint)

Demonstrated A1C results across 3 different studies^1-4

Mean change in A1C
from baseline at week 26

PIONEER 3
(vs. Januvia^®)²

All + MET ± SU

Y-AXIS:
MEAN CHANGE IN A1C FROM BASELINE (%)

PIONEER 2
(vs. Jardiance^®)³

Both + MET; open label

PIONEER 4
(vs. Victoza^® and placebo)⁴

All + MET ± SGLT2i

At week 52, the mean changes from baseline for A1C were -1.2% (RYBELSUS^® 14 mg),-0.9% (Victoza^® 1.8 mg), and -0.2% (placebo).

Y-AXIS:
MEAN CHANGE IN A1C FROM BASELINE (%)

Demonstrated weight results across 3 different studies (2° endpoint)^1-4

Mean change in weight
from baseline at week 26

PIONEER 3
(vs. Januvia^®)²

All + MET ± SU

Y-AXIS:
MEAN CHANGE IN WEIGHT FROM BASELINE (kg)

RYBELSUS^® is not indicated for weight reduction.

PIONEER 2
(vs. Jardiance^®)³

Both + MET; open label

PIONEER 4
(vs. Victoza^® and placebo)⁴

All + MET ± SGLT2i

At week 52, the mean changes from baseline in body weight were -4.3 kg (RYBELSUS^® 14 mg), -3.0 kg (Victoza^® 1.8 mg), and -1.0 kg (placebo).

Y-AXIS:
MEAN CHANGE IN WEIGHT FROM BASELINE (kg)

RYBELSUS^® is not indicated for weight reduction.

Adapted from the RYBELSUS^® Product Monograph;¹ Pratley RE, et al., 2019,⁴ see back for study design (PIONEER 4); Rodbard H, et al., 2019,³ see back for study design (PIONEER 2); Rosenstock J, et al., 2019,² see back for study design (PIONEER 3).

MET=metformin; NS=non-superiority; SGLT2i=sodium-glucose cotransporter-2 inhibitor; SU=sulfonylurea.

View Product Monograph

Help patients start once-daily RYBELSUS^®1

This regimen is intended to mitigate gastrointestinal symptoms during dose escalation.

No dose adjustment of RYBELSUS^® is recommended based on age, sex, race, ethnicity, upper gastrointestinal disease, or hepatic and renal impairment.

Patients can take RYBELSUS^® according to
the following instructions:¹

Take on an empty stomach,
e.g., upon waking

Swallow tablet whole with no
more than half a glass of water
(up to 120 mL)

Patients can be counselled to
swallow the tablet whole with a
sip of water

A larger volume of water is
likely to decrease the amount of
RYBELSUS^® absorbed

Wait at least 30 minutes before eating,
drinking, or taking any other
oral medication

Waiting <30 minutes is likely to decrease
the amount of RYBELSUS^® absorbed

• Tablets should not be split, crushed, or chewed

• Tablets must be stored in their original blister pack to protect them from moisture and light

Missed dose: If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day.

For management of a suspected drug overdose, contact your regional poison control centre.

Please see the Product Monograph for complete dosing, administration, and overdosage information.

If you have a specific question about RYBELSUS^®, please email our Medical Information team using this form. Our team will get back to you as soon as possible.